Italia markets open in 7 hours 33 minutes

BEAM May 2024 22.500 put

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
1,1500+0,1200 (+11,65%)
In data: 03:53PM EDT. Mercato aperto.
Schermo intero
Chiusura precedente1,0300
Aperto1,0000
Denaro1,0000
Lettera1,2000
Prezzo d'esercizio22,50
Scadenza2024-05-17
Min-Max giorno0,9500 - 1,1500
Contratto - Min-MaxN/D
Volume29
Open Interest298
  • GlobeNewswire

    Beam Therapeutics Presents Preclinical Data Highlighting Utility of BEAM-302 to Correct an Alpha-1 Antitrypsin (AAT) Deficiency Disease-Causing Mutation

    First Preclinical Data for BEAM-302 Demonstrate Increased Levels of Corrected AAT and Reduced Mutant PiZ AAT in Multiple In Vivo Rodent Disease ModelsCAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported new preclinical data demonstrating the ability of its in vivo drug candidate, BEAM-302, to directly correct the PiZ mutation, the primary disease-causing muta

  • GlobeNewswire

    Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL/T-LL

    BEAM-201 Represents First Quadruplex-edited, Allogeneic CAR-T Cell Therapy Candidate in Clinical-stage Development and First Treatment with a Base Editing Candidate in United States CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that in August, the first patient was treated with BEAM-201, a quadruplex-edited allogeneic CAR-T cell investigational therap

  • GlobeNewswire

    Beam Therapeutics to Participate in Upcoming September Investor Conferences

    CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management plans to participate in fireside chats during the following September investor conferences: Citi’s 18th Annual BioPharma Conference 2023 on Thursday, September 7, 2023 at 8:50 a.m. ET in Boston;2023 Wells Fargo Securities Healthcare Conference on Thursday, September 7, 2023 at 10:15 a.m. ET